News about 'treatment'

Enrollment has begun for a ground-breaking clinical program exploring the use of delamanid in paediatric multidrug-resistant tuberculosis (MDR-TB) . Otsuka is the first company to perform a trial among this population for regulatory approval. The programme will also evaluate the bioequivalence of a...

Click here to access full report Source: Treatment Action Group The Tuberculosis Treatment Pipeline June 2013 Better than Ever Is Not Good Enough By Erica Lessem Introduction In December 2012, tuberculosis (TB) treatment reached a historic landmark with the first approval by a stringent regulatory...

From the Stop TB Parntership News: The World Health Organization (WHO) has issued interim guidance on the use of bedaquiline, a new tuberculosis drug, for the treatment of multidrug-resistant tuberculosis (MDR-TB). Bedaquiline was granted accelerated approval by the United States Food and Drug...

Treatment Action Group (TAG) recently released its Spring 2013 issue of tagline, which contains three articles about TB research that might be of interest to you– 1) on rifapentine research and access , 2) on adaptive clinical trial designs , and 3) on pediatric drug development needs . The full...

World TB Day is celebrated on March 24 and there is a lot going on during this week and next to highlight the continued problem of TB in the world and the solutions to address the problem. Below is a list of publications, news items, events, and links related to TB and World TB Day 2013. EVENTS...

Press Release from FDA can be found at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm333695.htm . Press Release from Janssen is below. FDA Grants Accelerated Approval for SIRTURO™ (bedaquiline) as Part of Combination Therapy to Treat Adults with Pulmonary Multi-Drug Resistant...

Multidrug-Resistance Tuberculosis: No Promises from MSF Access Campaign on Vimeo . Patients with tuberculosis must undergo lengthy, arduous treatment regimens in the best of times. When stricken with multidrug-resistant tuberculosis, or MDR-TB, however, the road back to health is even more...

Yesterday, Nov. 28th, the FDA Ant-infective Drug Advisory Committee voted to recommend Janssen ‘s Bedaquiline for accelerated approval for the treatment of MDR tuberculosis. You can access materials from the meeting at http://www.fda.gov/AdvisoryCommittees/Calendar/ucm321011.htm . The sponsor and...

Anna K. Coussensa, Robert J. Wilkinson, Yasmeen Hanifa, Vladyslav Nikolayevskyy, Paul T. Elkington, Kamrul Islam, Peter M. Timms, Timothy R. Venton, Graham H. Bothamley, Geoffrey E. Packe, Mathina Darmalingam, Robert N. Davidson, Heather J. Milburn, Lucy V. Baker, Richard D. Barker, Charles A. Mein...

Yesterday, efficacy data from the first novel regimen trial (NC001) were published in the Lancet . The results found that the regimen containing PA-824, moxifloxacin, and pyrazinamide, could kill more than 99 percent of patients’ TB bacteria within two weeks and could be more effective than...

For this week’s update, we highlight three recent articles that look at repurposing and optimizing drugs already on the market or looking at novel targets and drug classes for TB. Dooley KE, Mitnick C, Degroote MA, Obuku E, Belitsky V, Hamilton CD, Makhene M, Shah S, Brust JC, Durakovic N,...

World TB Day Congressional Briefing Tuberculosis – We Can Beat this Global Killer Wednesday, March 21, 2012 A briefing and update on tuberculosis (TB), a disease that is curable but still takes the lives of 4,000 people each day and is the number one killer of people living with HIV. Special areas...

The 243rd American Chemistry Society National Meeting and Exposition is being held in San Diego, California, from March 26 to March 29. There are several presentations on tuberculosis. Here are the abstracts of a few of the talks. The first item received news coverage and discusses two approved...

At the 19th Conference on Retroviruses and Opportunistic Infections (CROI) in Seattle, results on the Thibela TB preventative therapy trial in South Africa gold miners was presented with mixed outcomes. On one hand, the number of cases in miners in the experimental group who screened negative for...

Dr. Tawanda Gumbo Summary: Dr. Tawanda Gumbo , an associate professor at the The University of Texas Southwestern Medical Center, recently published a paper in the Journal of Infectious Diseases entitled “Multidrug-resistant tuberculosis not due to noncompliance but to between-patient...